#USA #San Francisco #Securities Fraud #FTC Allegations #Hims & Hers

Hims & Hers Health Faces Securities Fraud Class Action

Hims & Hers Health, Inc. (NYSE: HIMS), along with several high-ranking executives, is currently embroiled in a securities class action lawsuit. This legal situation has arisen from significant allegations made by the Federal Trade Commission (FTC) highlighting serious business misconduct within the company. The implications of this lawsuit are severe, prompting investors to take action before the impending lead plaintiff deadline on November 2, 2026.

Background of the Lawsuit

The lawsuit, spearheaded by Hagens Berman, is focusing on various claims against Hims & Hers. The central issue revolves around the company's assurances regarding health and personal information management. Hims had previously advocated for robust measures ensuring data security and communication about health, but the FTC's allegations challenge the authenticity of these claims. The core allegations suggest that Hims took several questionable actions, leading to misrepresentation of its practices.

Among these claims, it is alleged that Hims shared sensitive consumer health information with third-party advertising platforms. This breach of trust not only poses ethical concerns but also raises questions about regulatory compliance and the ensuing financial repercussions. Moreover, the lawsuit points to practices such as prematurely charging consumers for prescriptions without adequate consultation from medical professionals, undermining the company's prior assurances about patient-centric care.

Key Allegations by the FTC

The FTC's complaint, filed on July 29, 2026, is particularly revealing. It outlines two main concerns:

1. Deceptive Health Data Practices: Despite marketing efforts that emphasize privacy and data security, the FTC claims that Hims inadequately safeguarded consumer health data. The accusation involves sharing sensitive health information with major tech firms like Meta Platforms and Snap, through tracking pixels and customer list matching, violating expectations of confidentiality.

2. Subscription Billing Misconduct: The lawsuit accuses Hims of breaching the Restore Online Shoppers' Confidence Act (ROSCA). This violation stems from enrolling customers into recurring subscription services without proper consent and rapidly billing them after they completed intake forms, even before receiving any medical consultation. Such practices create an environment where consumers face challenges in understanding their subscription status or canceling unwanted services.

The fallout from these allegations was immediate and severe. On July 29, 2026, the company's share price plummeted by $4.32, a staggering 14.7% drop, translating to a loss of over $970 million in market capitalization in just one day. This stock crash directly correlates with the FTC’s lawsuit, highlighting the potential impact of regulatory scrutiny on investor confidence.

The Path Forward for Investors

Hagens Berman is actively seeking information from Hims investors who may have suffered significant financial losses. They encourage those affected to reach out, aiming to gather more details that could substantiate the ongoing investigation. This outreach underscores the importance of collective action among investors during such turbulent times.

To aid in this effort, individuals can submit their losses through the firm's designated channels, and whistleblowers with non-public information are invited to participate in the investigation as well, potentially benefiting from the SEC Whistleblower program.

Conclusion

The situation remains fluid as Hims & Hers Health navigates these serious allegations. Investors are urged to be vigilant and proactive, particularly as the lead plaintiff deadline of November 2, 2026, approaches. As more details emerge from the ongoing investigation and litigation, the outcomes will undoubtedly affect the company's future and its investors’ holdings.